Mitogen-Activated Protein Kinase Inhibitor Selumetinib Fails to Increase the Complete Response Rate of Radioactive Iodine Alone in High-Risk Differentiated Thyroid Cancer: Lessons From the Phase III ASTRA Study.
Publication/Presentation Date
6-10-2022
Volume
40
Issue
17
First Page
1847
Last Page
1849
ISSN
1527-7755
Published In/Presented At
Brose, M. S., Pryma, D. A., & Newbold, K. L. (2022). Mitogen-Activated Protein Kinase Inhibitor Selumetinib Fails to Increase the Complete Response Rate of Radioactive Iodine Alone in High-Risk Differentiated Thyroid Cancer: Lessons From the Phase III ASTRA Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(17), 1847–1849. https://doi.org/10.1200/JCO.22.00556
Disciplines
Medicine and Health Sciences
PubMedID
35486879
Department(s)
Hematology-Medical Oncology Division
Document Type
Article
COinS